The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 103.50, with a high estimate of 220.00 and a low estimate of 50.00. The median estimate represents a +60.17% increase from the last price of 64.62.
The current consensus among 27 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$2.29
Reporting Date Nov 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.